Scleroderma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
Line 19: | Line 19: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] |
Latest revision as of 00:05, 30 July 2020
Scleroderma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Scleroderma laboratory findings On the Web |
American Roentgen Ray Society Images of Scleroderma laboratory findings |
Risk calculators and risk factors for Scleroderma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
Specific laboratory findings consistent with the diagnosis of scleroderma include: Anti-Scl-70 antibody (Topoisomerase I), anti-centromere antibody (CREST syndrome), anti-nuclear antibody (ANA), anti-RNA polymerase III antibody, anti-U1-RNP antibody.
Laboratory Findings
Laboratory findings consistent with the diagnosis of scleroderma include:[1]
- Anti-Scl-70 antibody (Topoisomerase I)
- Anti-centromere antibody (CREST syndrome)[2]
- Anti-nuclear antibody (ANA)
- Anti-RNA polymerase III antibody
- Anti-U1-RNP antibody
References
- ↑ Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (June 1980). "Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome". Arthritis Rheum. 23 (6): 617–25. PMID 6155920.
- ↑ Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (October 1984). "The anticentromere antibody: disease specificity and clinical significance". Mayo Clin. Proc. 59 (10): 700–6. PMID 6384675.